Propanc Biopharma, Inc.
PPCB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | – | 50% | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $4 | $53 | $0 |
| SG&A Expenses | $0 | $4 | $53 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $5 | $0 | -$0 | -$0 |
| Operating Expenses | $5 | $4 | $53 | $0 |
| Operating Income | -$5 | -$4 | -$53 | -$0 |
| % Margin | – | -12,189.8% | – | – |
| Other Income/Exp. Net | -$0 | -$0 | -$1 | -$0 |
| Pre-Tax Income | -$5 | -$4 | -$54 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5 | -$4 | -$54 | -$0 |
| % Margin | – | -13,615.1% | – | – |
| EPS | -0.39 | -0.35 | -12.5 | -32.22 |
| % Growth | -11.4% | 97.2% | 61.2% | – |
| EPS Diluted | -0.39 | -0.35 | -12.5 | -32.22 |
| Weighted Avg Shares Out | 12 | 12 | 4 | 0 |
| Weighted Avg Shares Out Dil | 12 | 12 | 4 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $0 | $0 | $0 |
| EBITDA | -$2 | -$4 | -$54 | -$0 |
| % Margin | – | -12,746.4% | – | – |